A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...

Five therapies are currently approved by the FDA for treating the symptoms of myasthenia gravis, allowing partial to complete remission. Research suggests that five new therapies may become available ...

The first study to use an RNA-based chimeric antigen receptor T-cell (rCAR-T) therapy in autoimmune disease showed people with generalized myasthenia gravis tolerated the treatment well and ...

SAVANNAH, Ga. — Should patients with myasthenia gravis (MG) continue to undergo the traditional therapy of immunosuppression with drugs like corticosteroids and nonsteroidal agents? Or is it time to ...

Richard J. Nowak, MD, is director of the Myasthenia Gravis Clinic, director of Clinical & Translational Neuromuscular Research (CTNR), and associate professor of neurology at Yale School of Medicine.

A real-world study of health care resource utilization (HCRU) in patients with myasthenia gravis on second-line therapy identified the factors that led to increased financial burdens. A recent study ...

Only 6% to 12% of patients with MG are truly seronegative (i.e., have negative standard assays for AChR antibodies and MuSK antibodies). 8 These individuals may also be referred to as double negative, ...

World Myasthenia Gravis Day is celebrated every June 15 th. Myasthenia gravis (MG) is an autoimmune illness that affects approximately 1.5 to 2 million people globally. The disorder is characterized ...